RecruitingNCT07546682
Propel Drug-Eluting Sinus Implant Family IBUKI Cohort
Sponsor
Medtronic
Enrollment
100 participants
Start Date
Apr 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying None, observational standard of care study for people with chronic rhinosinusitis (crs). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNone, observational standard of care study
None, observational standard of care study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07546682
Related Trials
Triamcinolone Nanocapsules After Endoscopic Nasal Surgery
NCT077145251 location
Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training
NCT076819731 location
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
NCT069969511 location
Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures
NCT072994741 location
Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms
NCT0726245032 locations